Toward a predictive theoretical model for osmolality rise with non-humidified incubation: a randomized, multivariate response-surface study

2021 ◽  
Author(s):  
Steven F Mullen

Abstract STUDY QUESTION What factors associated with embryo culture techniques contribute to the rate of medium osmolality change over time in an embryo culture incubator without added humidity? SUMMARY ANSWER The surface area-to-volume ratio of culture medium (surface area of the medium exposed to an oil overlay), as well as the density and height of the overlaying oil, all interact in a quantitative way to affect the osmolality rise over time. WHAT IS KNOWN ALREADY Factors such as medium volume, different oil types, and associated properties, individually, can affect osmolality change during non-humidified incubation. STUDY DESIGN, SIZE, DURATION Several experimental designs were used, including simple single-factor completely randomized designs, as well as a multi-factor response surface design. Randomization was performed at one or more levels for each experiment. Osmolality measurements were performed over 7 days, with up to 8 independent osmolality measurements performed per treatment group over that time. For the multi-factor study, 107 independent combinations of factor levels were assessed to develop the mathematical model. PARTICIPANTS/MATERIALS, SETTING, METHODS This study was conducted in a research laboratory setting. Commercially available embryo culture medium and oil was used. A MINC incubator without water for humidification was used for the incubation. Osmolality was measured with a vapor pressure osmometer after calibration. Viscometry and density were conducted using a rheometer, and volumetric flasks with an analytical balance, respectively. Data analyses were conducted with several commercially available software programs. MAIN RESULTS AND THE ROLE OF CHANCE Preliminary experiments showed that the surface area-to-volume ratio of the culture medium, oil density, and oil thickness above the medium all contributed significantly (P < 0.05) to the rise in osmolality. A multi-factor experiment showed that a combination of these variables, in the form of a truncated cubic polynomial, was able to predict the rise in osmolality, with these three variables interacting in the model (P < 0.05). Repeatability, as measured by the response of identical treatments performed independently, was high, with osmolality values being ± 2 of the average in most instances. In the final mathematical model, the terms of the equation were significant predictors of the outcome, with all P-values being significant, and only one P-value > 0.0001. LIMITATIONS, REASONS FOR CAUTION Although the range of values for the variables were selected to encompass values that are expected to be encountered in usual embryo culture conditions, variables outside of the range used may not result in accurate model predictions. Although the use of a single incubator type and medium type is not expected to affect the conclusions, that remains an uncertainty. WIDER IMPLICATIONS OF THE FINDINGS Using this predictive model will help to determine if one should be cautious in using a specific system and will provide guidance on how a system may be modified to provide improved stability during embryo culture. STUDY FUNDING/COMPETING INTEREST(S) This study was funded by Cook Medical. The author is a Team Lead and Senior Scientist at Cook Medical. The author has no other conflicts of interest to declare TRIAL REGISTRATION NUMBER N/A.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4256-4256
Author(s):  
Michael Plietz ◽  
Aaron Leifer ◽  
Vilma Padilla ◽  
Carole Pineda ◽  
Khrishan Naraine ◽  
...  

Abstract Abstract 4256 Background: Activated clotting time (ACT) is determined during cardiac procedures in order to assess the level of anti-coagulation. There are three main anticoagulants used during cardiac procedures:heparin, angiomax and Plavix. Heparin is often used in the cardiac OR for major procedures and is neutralized, over time, by platelet factor 4(PF4). Angiomax, bivalirudin, has a quick onset of action, but a much shorter half-life when compared to Heparin. Plavix, clopidogrel, irreversibly inhibits platelets from clotting and is used on patients in need of anticoagulation for an extended period of time. The purpose of this study was to evaluate the stability of ACT results over time utilizing different coagulation regimens. If the ACT value remains stable over time, this would enable us to remove the device from the OR and place it in a stat laboratory. Methods: ACTs were determined by the ISTAT (Abbott), a hand held point of care device, using kaolin activated cartridges. A single blood sample was obtained and was evaluated at intervals of 0, 5, 10, 15, and 20 minutes. In addition, temperature, age, body surface area and platelet count of patient were recorded. The time 0 specimen was used to determine the patients ACT and interval testing was performed on the remnant. Results: 36 samples representing 22 patients had ACT tests performed using the ISTAT. There was no significant change from 0 to 20 minutes over the entire dada set. However, when divided into different anti-clotting agents there were significant changes. Patients who had only taken Angiomax had a significant difference within the first 5 minutes (p value=.0094). Patients taking Angiomax and Plavix together had no change in ACT values at 20 minutes. Patients on Heparin alone demonstrated a loss of ACT stability at 10 minutes with values both increasing and decreasing. Conclusions: Patients on Angiomax alone demonstrated a significant difference in ACT value within the first 5 minutes and all intervals thereafter. Based on Angiomax short half-life the ACT should be performed as soon as possible. The ACT values in patients taking both Angiomax and Plavix achieved steady state throughout the 20 minutes and had little if any decrease in value. The results for the Heparin group were unreliable at 10 minutes. As a result of these findings, performing an ACT outside the OR is feasible assuming the test can be performed by 10 minutes. Disclosures: No relevant conflicts of interest to declare.


2017 ◽  
Vol 8 (1-2) ◽  
pp. 57-62
Author(s):  
Omar Masabni ◽  
Michelle Wheater

Aims and Objectives: Cytotoxicity assays are one of the methods used to assess the biocompatibility of dental materials. The objective of this study was to determine if surface area/volume ratios designated by the International Organization for Standardization (ISO) for biological evaluation of medical devices affects cytotoxicity and calcium release in an endodontic pulp-capping materials. Material and Methods: Human periodontal ligament fibroblasts (PDLFb) were treated with extractables derived from the calcium silicate pulp-capping material TheraCal LC at pellet surface area/culture medium volume ratios of 0.2, 0.5, and 1.0 cm2/mL. A colorimetric cytotoxicity assay (MTT) and phase-contrast microscopy was used to assess biocompatibility against the fibroblasts. The concentration of calcium leached into culture medium from TheraCal LC at pellet surface area/culture medium volume ratios of 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, and 6.0 cm2/mL after 24 hours was determined by colorimetric assay. Results: Both MTT assays and microscopy demonstrate that at a pellet surface area/culture medium volume ratio of 1.0 cm2/mL TheraCal LC extractable challenge to fibroblasts results in a significant decrease in cell viability ( P < 0.001) compared to control. TheraCal LC calcium release into culture medium varied with the surface area/volume ratio, with concentrations ranging from 2 to 8 times the calcium concentration in culture medium. Conclusion: Pellet surface area/culture medium volume ratios impacted parameters of TheraCal LC used in in vitro studies to determine biocompatibility with oral tissues. The ISO guidelines should be followed for all in vitro cytotoxicity studies of dental materials.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 2054-2054
Author(s):  
Aryeh Pelcovits ◽  
Giancarlo Riotto ◽  
Katie Cherenzia ◽  
Patrick T. McGann ◽  
John L Reagan

Abstract Introduction: Hydroxyurea (HU) was the first FDA-approved therapy for sickle cell anemia (SCA) and remains the most well-established disease-modifying therapy, reducing painful crisis and improving morbidity and mortality. HU improves outcomes through the upregulation of fetal hemoglobin (HbF). Dosing is highly variable with doses ranging from &lt;10-35 mg/kg/day. Most dosing strategies escalate with a goal of mild myelosuppression, commonly defined using an absolute neutrophil count (ANC) between 2,000-4,000 and platelets &gt;80,000. Macrocytosis is often used as a surrogate marker for compliance and effect. Despite its well-established effectiveness, clinical use remains limited with only 12% of adults with SCA taking HU. The reasons for this are multifactorial but include skepticism by both providers and patients regarding its effectiveness in the adult population. Some experts suggest up to 30% of adults are non-responders with no significant HbF change, and many believe that the effect of HU fades with time. Dosing strategies are usually quite conservative to prevent excessive myelosuppression, though dose is highly correlated with clinical effect and ultimate %HbF. There is very limited real-world data regarding long term effectiveness of HU in adults with SCA over time. Methods: We retrospectively analyzed the records of the 109 adults with SCA currently treated in our multidisciplinary sickle cell clinic. Data from 1/1/2011-6/30/2021 was collected, including genotype, HU prescription status, current and maximum laboratory values (HbF, MCV, ANC), and number of admissions for painful crisis. We performed Wilcoxon rank sum testing between pts prescribed and not prescribed HU and measures of HbF (peak, average and current) and number of admissions for painful crisis over the study period. Results: Among 106 pts (3 excluded from analysis, 2 for lack of data and 1 for post-transplant status), 79 are currently prescribed HU (75%). Among our 63 pts with HbSS genotype 58 are prescribed HU (92%). Average HbF over time for all pts prescribed HU was 11.9%. Average peak HbF was 18.1% and average current HbF is 12.4%. In the pts not prescribed HU HbF average, peak and current levels were 5.5%, 6.7%, and 5.0% respectively. HU prescription was significantly associated with increased HbF at peak, average, and current levels (p-value &lt;0.001, Figure A). HU prescription was also significantly associated with decreased number of admissions for painful crisis (p-value 0.001). Among pts prescribed HU, MCV levels &gt;100 at time of peak HbF were associated with higher peak levels than pts with MCV &lt;100 (p-value &lt;0.001, Figure B). Larger peak HU doses were also correlated with higher MCVs at the time of peak HbF levels (Figure C). Larger current HU doses were also significantly associated with higher current HbF levels (Figure, D). Doses &gt;9.9m/kg were associated with significantly higher HbF levels however there was no significant difference between dose levels 10-19.9mg/kg and 20-29.9 or 20-29.9 and 30-39.9mg/kg (p-values 0.02, 0.68 and 0.84 respectively). Among pts prescribed HU, 34 obtained ANC levels &lt;4000 at the times of peak HbF and 24 at the current dosing level (43% and 30% respectively). 24 pts obtained both MCV&gt;100 and ANC &lt;4000 at time of peak HbF and only 11 achieved both at current dosing levels (30% and 14% respectively). Conclusion: In our adult multidisciplinary sickle cell clinic prescribing rates are well above current HU usage for adults with SCA. Our data notes that elevated HbF levels can be maintained over long periods of time. HU prescription was significantly associated with increased HbF levels and reduced admissions for painful crisis. This was despite a majority of pts not meeting target prescribing levels of ANC &lt;4000 and MCV &gt;100. While higher peak HbF levels were significantly associated with higher HU doses, this was only true for doses above 9.9 mg/kg. Further investigation is needed to explore the factors contributing to suboptimal HbF and MCV response, including careful assessment with medication adherence and dose selection. Overall, these data illustrate the importance of dosing and suggest that one size dosing of HU for adults with SCA does not fit all. We hypothesize that there may be a role individualized dosing strategies in adults with SCA, incorporating factors such as pharmacokinetics and renal function to achieve the optimal dose for each patient. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2204-2204
Author(s):  
Catherine Lemarie ◽  
Jianqiu Wu ◽  
Jake Barralet ◽  
Mark Blostein

Abstract Abstract 2204 We have previously shown that ideal amphipathic peptides (IAP) composed simply of leucine and lysine residues can augment the function of the procoagulant enzyme, factor IX in vitro (Biochem J 2008). We have also shown that surface attachment of IAP can promote hemostasis and reduce bleeding in vivo. We extend these observations by coupling IAPs to a nanomaterial called nanofibrousmicrospheres (NFM). NFMs have a large surface area to volume ratio thereby providing greater surface area and better access to bleeding surfaces especially those that are internal and difficult to reach. Initially we demonstrate, by fluorescently labeling IAP with dansyl chloride, that IAP attaches to NFM. When free dansyl IAP is added to NFM, 90% binds to the surface of NFM via a non-covalent linkage. Both a murine liver laceration model and a murine tail transection model were established to evaluate the in vivo hemostatic properties of IAP attached to NFM (IAP-NFM). In a murine liver laceration model, where the liver is cut with a Surgicutt template, application of IAP-NFM significantly reduces bleeding times by 40% as compared to application of NFM alone (p<0.01), or no treatment (p<0.01). As well, comparison of IAP-NFM to QuikClot, a current commercially used product for control of hemorrhagic injuries, show a greater reduction in bleeding times after application of IAP-NFM as compared to QuikClot. In addition, histologic examination of the lacerated liver after treatment reveal that IAP-NFM elicited little tissue injury whereas widespread hepatocyte injury was caused by QuikClot, due to its known exothermic reaction on tissue. The bleeding time in a murine tail transection model was also reduced by approximately 30% by IAP-NFM, as compared to NFM alone (p<0.01), or no treatment (p<0.05). In conclusion, IAP attachment to NFM results in a biocompatible material that is procoagulant and can promote hemostasis in vivo with the advantage that it exhibits little tissue injury after its application. Disclosures: No relevant conflicts of interest to declare.


Author(s):  
Vikas D Singhai ◽  
Rahul Maheshwari ◽  
Swapnil Sharma ◽  
Sarvesh Paliwal

Background: Heart attack predominantly occurs during the last phase of sleep and early morning hours, causing millions of death worldwide. Hydrochlorothiazide (HCTZ) is recommended drug for the prevention of heart disease but its long action (>4 h) dosage form is lacking in the commercial market and development of extended-release formulation may have industrial significance. Regulatory agencies emphasize Quality by Design based approach for product development to entrust quality in the product. Objective: Aim of the current research was to develop a quality product profile of HCTZ modified-release tablets (MRT; ~14 h) by applying Response Surface Methodology using computational QbD approach. Methods: Three independent factors were identified by qualitative and quantitative risk assessment. Statistical terms like p-value, lack of fit, sum of square, R-squared value, model F value and linear equations were determined. Graphical tools like normal plot of residual, residual vs predicted plot and box cox plot were used to verify model selection. Graphical relationship among the critical, independent variables was represented using the Contour plot and 3-D surface plot. Design space was identified by designing overlay plot using response surface design. Results: Excellent correlation was observed between actual and predicted values. Similarity Factor (F2) of reproducible trials was 78 and 79 and content uniformity was 100.9% and 100.4%. Average weight, hardness, thickness, diameter and friability were within acceptable limits. Conclusions: QbD approach along with quality risk management tool provided an efficient and effective paradigm to build quality MRT of HCTZ.


2018 ◽  
Vol 9 (1) ◽  
pp. 79-84
Author(s):  
Vaishali V. Shahare ◽  
Rajni Grover ◽  
Suman Meena

Background: The persistent dioxins/furans has caused a worldwide concern as they influence the human health. Recent research indicates that nonmaterial may prove effective in the degradation of Dioxins/furans. The nanomaterials are very reactive owing to their large surface area to volume ratio and large number of reactive sites. However, nanotechnology applications face both the challenges and the opportunities to influence the area of environmental protection. Objective: i) To study the impact of oil mediated UV-irradiations on the removal of 2,3,7,8-TCDD, 2,3,7,8-TCDF, OCDD and OCDF in simulated soil samples. ii) To compare the conventional treatment methods with the modern available nanotechniques for the removal of selected Dioxins/furans from soil samples. Methods: The present work has investigated an opportunity of the degradation of tetra and octachlorinated dioxins and furans by using oil mediated UV radiations with subsequent extraction of respective dioxins/furans from soils. The results have been compared with the available nanotechniques. Results: The dioxin congeners in the simulated soil sample showed decrease in concentration with the increase in the exposure time and intensity of UV radiations. The dechlorination of PCDD/Fs using palladized iron has been found to be effective. Conclusion: Both the conventional methods and nanotechnology have a dramatic impact on the removal of Dioxins/furans in contaminated soil. However, the nanotechniques are comparatively costlier and despite the relatively high rates of PCDDs dechlorination by Pd/nFe, small fraction of the dioxins are recalcitrant to degradation over considerable exposure times.


2021 ◽  
Vol 14 ◽  
pp. 117862212110281
Author(s):  
Ahmed S. Mahmoud ◽  
Nouran Y. Mohamed ◽  
Mohamed K. Mostafa ◽  
Mohamed S. Mahmoud

Tannery industrial effluent is one of the most difficult wastewater types since it contains a huge concentration of organic, oil, and chrome (Cr). This study successfully prepared and applied bimetallic Fe/Cu nanoparticles (Fe/Cu NPs) for chrome removal. In the beginning, the Fe/Cu NPs was equilibrated by pure aqueous chrome solution at different operating conditions (lab scale), then the nanomaterial was applied in semi full scale. The operating conditions indicated that Fe/Cu NPs was able to adsorb 68% and 33% of Cr for initial concentrations of 1 and 9 mg/L, respectively. The removal occurred at pH 3 using 0.6 g/L Fe/Cu dose, stirring rate 200 r/min, contact time 20 min, and constant temperature 20 ± 2ºC. Adsorption isotherm proved that the Khan model is the most appropriate model for Cr removal using Fe/Cu NPs with the minimum error sum of 0.199. According to khan, the maximum uptakes was 20.5 mg/g Cr. Kinetic results proved that Pseudo Second Order mechanism with the least possible error of 0.098 indicated that the adsorption mechanism is chemisorption. Response surface methodology (RSM) equation was developed with a significant p-value = 0 to label the relations between Cr removal and different experimental parameters. Artificial neural networks (ANNs) were performed with a structure of 5-4-1 and the achieved results indicated that the effect of the dose is the most dominated variable for Cr removal. Application of Fe/Cu NPs in real tannery wastewater showed its ability to degrade and disinfect organic and biological contaminants in addition to chrome adsorption. The reduction in chemical oxygen demand (COD), biological oxygen demand (BOD), total suspended solids (TSS), total phosphorus (TP), total nitrogen (TN), Cr, hydrogen sulfide (H2S), and oil reached 61.5%, 49.5%, 44.8%, 100%, 38.9%, 96.3%, 88.7%, and 29.4%, respectively.


Foods ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1741
Author(s):  
Xin Sun ◽  
Jialing Vivien Chua ◽  
Quynh Anh Le ◽  
Francisco Trujillo ◽  
Mi-Hwa Oh ◽  
...  

The response surface methodology (RSM) and central composite design (CCD) technique were used to optimize the three key process parameters (i.e., pressure, temperature and holding time) of the high-hydrostatic-pressure (HHP) processing either standalone or combined with moderate thermal processing to modulate molecular structures of β-lactoglobulin (β-Lg) and α-lactalbumin (α-La) with reduced human IgE-reactivity. The RSM model derived for HHP-induced molecular changes of β-Lg determined immunochemically showed that temperature (temp), pressure (p2) and the interaction between temperature and time (t) had statistically significant effects (p < 0.05). The optimal condition defined as minimum (β-Lg specific) IgG-binding derived from the model was 505 MPa at 56 °C with a holding time of 102 min (R2 of 0.81 and p-value of 0.01). The validation carried at the optimal condition and its surrounding region showed that the model to be underestimating the β-Lg structure modification. The molecular change of β-Lg was directly correlated with HHP-induced dimerization in this study, which followed a quadratic equation. The β-Lg dimers also resulted in the undetectable human IgE-binding.


2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 547.1-547
Author(s):  
C. Deakin ◽  
G. Littlejohn ◽  
H. Griffiths ◽  
T. Smith ◽  
C. Osullivan ◽  
...  

Background:The availability of biosimilars as non-proprietary versions of established biologic disease-modifying anti-rheumatic drugs (bDMARDs) is enabling greater access for patients with rheumatic diseases to effective medications at a lower cost. Since April 2017 both the originator and a biosimilar for etanercept (trade names Enbrel and Brenzys, respectively) have been available for use in Australia.Objectives:[1]To model effectiveness of etanercept originator or biosimilar in reducing Disease Activity Score 28-joint count C reactive protein (DAS28CRP) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) treated with either drug as first-line bDMARD[2]To describe persistence on etanercept originator or biosimilar as first-line bDMARD in patients with RA, PsA or ASMethods:Clinical data were obtained from the Optimising Patient outcomes in Australian rheumatoLogy (OPAL) dataset, derived from electronic medical records. Eligible patients with RA, PsA or AS who initiated etanercept originator (n=856) or biosimilar (n=477) as first-line bDMARD between 1 April 2017 and 31 December 2020 were identified. Propensity score matching was performed to select patients on originator (n=230) or biosimilar (n=136) with similar characteristics in terms of diagnosis, disease duration, joint count, age, sex and concomitant medications. Data on clinical outcomes were recorded at 3 months after baseline, and then at 6-monthly intervals. Outcomes data that were missing at a recorded visit were imputed.Effectiveness of the originator, relative to the biosimilar, for reducing DAS28CRP over time was modelled in the matched population using linear mixed models with both random intercepts and slopes to allow for individual heterogeneity, and weighting of individuals by inverse probability of treatment weights to ensure comparability between treatment groups. Time was modelled as a combination of linear, quadratic and cubic continuous variables.Persistence on the originator or biosimilar was analysed using survival analysis (log-rank test).Results:Reduction in DAS28CRP was associated with both time and etanercept originator treatment (Table 1). The conditional R-squared for the model was 0.31. The average predicted DAS28CRP at baseline, 3 months, 6 months, 9 months and 12 months were 4.0 and 4.4, 3.1 and 3.4, 2.6 and 2.8, 2.3 and 2.6, and 2.2 and 2.4 for the originator and biosimilar, respectively, indicating a clinically meaningful effect of time for patients on either drug and an additional modest improvement for patients on the originator.Median time to 50% of patients stopping treatment was 25.5 months for the originator and 24.1 months for the biosimilar (p=0.53). An adverse event was the reason for discontinuing treatment in 33 patients (14.5%) on the originator and 18 patients (12.9%) on the biosimilar.Conclusion:Analysis using a large national real-world dataset showed treatment with either the etanercept originator or the biosimilar was associated with a reduction in DAS28CRP over time, with the originator being associated with a further modest reduction in DAS28CRP that was not clinically significant. Persistence on treatment was not different between the two drugs.Table 1.Respondent characteristics.Fixed EffectEstimate95% Confidence Intervalp-valueTime (linear)0.900.89, 0.911.5e-63Time (quadratic)1.011.00, 1.011.3e-33Time (cubic)1.001.00, 1.007.1e-23Originator0.910.86, 0.960.0013Acknowledgements:The authors acknowledge the members of OPAL Rheumatology Ltd and their patients for providing clinical data for this study, and Software4Specialists Pty Ltd for providing the Audit4 platform.Supported in part by a research grant from Investigator-Initiated Studies Program of Merck & Co Inc, Kenilworth, NJ, USA. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck & Co Inc, Kenilworth, NJ, USA.Disclosure of Interests:Claire Deakin: None declared, Geoff Littlejohn Consultant of: Over the last 5 years Geoffrey Littlejohn has received educational grants and consulting fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Novartis, Pfizer, Janssen, Sandoz, Sanofi and Seqirus., Hedley Griffiths Consultant of: AbbVie, Gilead, Novartis and Lilly., Tegan Smith: None declared, Catherine OSullivan: None declared, Paul Bird Speakers bureau: Eli Lilly, abbvie, pfizer, BMS, UCB, Gilead, Novartis


Sign in / Sign up

Export Citation Format

Share Document